Innate Pharma (IPHA) Projected to Post Earnings on Tuesday

Innate Pharma (NASDAQ:IPHA - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Innate Pharma to post earnings of ($0.27) per share and revenue of $18.24 million for the quarter.

Innate Pharma Trading Up 2.5 %

NASDAQ:IPHA traded up $0.06 during midday trading on Friday, reaching $2.44. 44,929 shares of the stock traded hands, compared to its average volume of 186,085. The company has a fifty day moving average of $2.00 and a 200 day moving average of $1.91. Innate Pharma has a 12 month low of $1.29 and a 12 month high of $3.51.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $11.00 target price (down from $11.50) on shares of Innate Pharma in a report on Thursday, April 24th.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.